Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465618 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
A Phase 1 study of Brain Cancer and Pituitary Adenoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03465618: Active Phase 1 study of Brain Cancer and Pituitary Adenoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03465618 is a Phase 1 study of Brain Cancer and Pituitary Adenoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03465618, a Phase 1 study of Brain Cancer and Pituitary Adenoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test if PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles, can be used to take pictures of brain tumors. The investigators want to understand how the particles are distributed and removed from the body, which may help others be treated in the future. This will be the first time that 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles are being used in people. The amount of particles given in this study is very small compared to the amount that was used in mice animal studies.
Primary Outcome
using serial PET imaging and/or correlative histologyFollowing tumor biopsy or surgical resection, histologic assessments will be performed using autoradiography to visualize the distribution of this agent within tumor tissue specimens.
Conditions Studied
Interventions
- DRUG 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
- OTHER Blood and Urine samples
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT03465618 still lists
NCT03465618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Brain Cancer appearing as the primary indexed condition, and to 2 interventions - of which 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging is the first listed.
NCT03465618 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03465618 about?
NCT03465618 is a clinical study titled "A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors". The purpose of this study is to test if PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles, can be used to take pictures of brain tumors. The investigators want to understand how the particles are distributed and removed from the body, which may help others be treated in the future. This will b...
What is the current status of trial NCT03465618?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-03-07. Estimated completion is 2026-03.
What conditions does trial NCT03465618 study?
This clinical trial studies the following conditions: Brain Cancer, Pituitary Adenoma.
What interventions are being tested in trial NCT03465618?
The interventions under investigation include: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging (DRUG), Blood and Urine samples (OTHER).
Who is sponsoring clinical trial NCT03465618?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03465618 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03465618's enrollment target sits among peer trials
17 40th of 47 higher than 7 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI